Phase II Study of Oral Metformin for Intravesical Treatment of Non-muscle-invasive Bladder Cancer

Phase 2 Recruiting 49 enrolled Academic Medical Center - University of Amsterdam Radboud University Medical Center · collab

NaSingle-groupOpen-labelTreatment

Summary

A multi-center, open-label, phase II clinical study of metformin in up to evaluable 49 patients with low-grade NMIBC with the aim to determine the overall response to administration of oral metformin for 3 months in a index papillary NMIBC tumour.

Timeline

Start: 2019-09-01
Primary completion: 2024-07-31
Completion: 2029-10-01

Publications

Molenaar RJ, van Hattum JW, Brummelhuis IS, Oddens JR, Savci-Heijink CD, Boeve ER, van der Meer SA, Witjes JF, Pollak MN, de Reijke TM, Wilmink JW. Study protocol of a phase II clinical trial of oral metformin for the intravesical treatment of non-muscle invasive bladder cancer. BMC Cancer. 2019 Nov 21;19(1):1133. doi: 10.1186/s12885-019-6346-1.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Metformin	Small molecule	1500 mg	Oral

Phase II Study of Oral Metformin for Intravesical Treatment of Non-muscle-invasive Bladder Cancer

Summary

Timeline

Publications

Drugs

Indications